Ribonucleotide Reductase Allosteric Modulators for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapies targeting ribonucleotide reductase for cancer treatment are nucleoside-based and cause nonspecific binding, leading to unwanted side effects due to their promiscuity, necessitating the development of specific allosteric modulators to inhibit neoplastic cell growth.
Innovation Solution
Development of ribonucleotide reductase allosteric modulators (RRAmods) that target the hexamer interface of the enzyme to modulate its activity, specifically inhibiting neoplastic cell growth by binding to the hexamer interface of ribonucleotide reductase, thereby affecting de novo DNA synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside-based chemotherapies are used to target ribonucleotide reductase, then RR activity is inhibited, but nonspecific binding occurs leading to unwanted side effects
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the allosteric site of ribonucleotide reductase rather than the active site. This localized targeting ensures that the inhibition is specific to RR and does not affect other nucleoside binding proteins, thereby resolving the contradiction between achieving RR inhibition and avoiding nonspecific side effects
Solution Approach 2:
The invention uses allosteric modulators as intermediaries to indirectly inhibit RR activity. Instead of directly competing with nucleoside substrates at the active site, these compounds bind to the allosteric site and modulate enzyme activity through conformational changes, providing specific inhibition without the promiscuity of nucleoside-based therapies
2Productivity
If existing chemotherapies are used to treat neoplastic cells, then cell growth is inhibited, but promiscuous binding to other nucleoside binding proteins causes unwanted side effects
Solution Approach 1:
The patent segments the functional sites of ribonucleotide reductase by targeting the allosteric site separately from the active site. This segmentation allows for selective inhibition of RR without affecting other nucleoside binding proteins, enabling effective cancer treatment while minimizing harmful side effects from promiscuous binding
Solution Approach 2:
The invention changes the binding parameters by using compounds with specific structural features (such as hydroxylamine or nitroamine groups) that preferentially bind to the allosteric site of RR. This parameter change in binding specificity enables potent inhibition of neoplastic cell growth while avoiding the promiscuity that causes side effects
Data Source
AI summary
A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.